DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03807440
• Other study ID #: 1245-0187
• Status: Completed
• Start date: August 26, 2019
• Est. completion date: August 31, 2021

Study information

• Verified date: February 2023
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a non-interventional study using existing data including medical chart review.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4083
• Est. completion date: August 31, 2021
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent prior to participation

2. Female and male patients age = 18 years

3. Patients with T2D diagnosis

4. Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)

5. Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

Exclusion Criteria:

1. Patients age < 18 years

2. Patients with diagnosis of other types of diabetes than T2D

3. Patients who do not provide written consent to the terms of the study

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2

Intervention

Drug:
• Empagliflozin
Empagliflozin
• Sodium Glucose Transporter 2 inhibitor
Sodium Glucose Transporter 2 inhibitor
• Dipeptidyl-peptidase 4 inhibitor
Dipeptidyl-peptidase 4 inhibitor
• Glucagon-like peptide 1 agonist
Glucagon-like peptide 1 agonist

Locations

Country	Name	City	State
Bulgaria	MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903	Byala
Bulgaria	MC "Diamedical 2013" OOD, Center Nr.: 35902	Dimitrovgrad
Bulgaria	MBAL- Dobrich AD, Center Nr.: 35916	Dobrich
Bulgaria	Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904	Dupnitsa
Bulgaria	MC Kuchuk Parij OOD, Center Nr.: 35906	Plovdiv
Bulgaria	MHAT "Medline Clinic", Center Nr.: 35911	Plovdiv
Bulgaria	MC Saint Elisaveta-Rakovski EOOD, Center Nr.: 35909	Rakovski
Bulgaria	"Medical Center-Razgrad"OOD, Center Nr.: 35910	Razgrad
Bulgaria	DCC 1 - Russe EOOD, Center Nr.: 35905	Russe
Bulgaria	MBAL "Hadzhi Dimitar" OOD, Center Nr.: 35915	Sliven
Bulgaria	MC "Vitaclinic" EOOD, Center Nr.: 35901	Sofia
Bulgaria	MC Gina - LZ SIMP EOOD, Center Nr.: 35918	Sofia
Bulgaria	MC Kalimat EOOD, Center Nr.: 35914	Sofia
Bulgaria	MC Polimed AD, Center Nr.: 35907	Sofia
Bulgaria	Acibadem City Clinic Medical Center Varna EOOD, Center Nr.: 35908	Varna
Czechia	Michal Brada, Center Nr.: 42001	Beclav
Czechia	Dr. Kovaová, Center Nr.: 42069	Beroun
Czechia	Practice Dr. Alice Sýkorová, Center Nr.: 42057	Bilina
Czechia	MUDr. Alica Vesela, Center Nr.: 42030	Broumov
Czechia	EUC Klinika eské Budjovice, Center Nr.: 42052	Eské Budjovice
Czechia	Lékaský dm Géko, Center Nr.: 42059	Eské Budjovice
Czechia	Barbara Buzová, Center Nr.: 42003	Havíov
Czechia	Zaviatiová, Petra, Center Nr.: 42004	Havíov
Czechia	Radana Syslová, Center Nr.: 42035	Hlušovice
Czechia	Pavel Kasík, Center Nr.: 42046	Hoovice
Czechia	Practice Dr. Petr Maule, Center Nr.: 42054	Humpolec
Czechia	Mediab Jihlava s.r.o., Center Nr.: 42066	Jihlava
Czechia	Practice MUDr. Gita Markofová, Center Nr.: 42053	Karlovy Vary
Czechia	Dr. Konená, Center Nr.: 42036	Karviná - Staré Msto
Czechia	Practice Zdzislaw Wranka, Center Nr.: 42072	Karviná-Hranice
Czechia	Pavel Tománek, Center Nr.: 42028	Kopivnice
Czechia	DIABET HELP s.r.o., Center Nr.: 42058	Kralupy nad Vltavou
Czechia	MUDr.Tomáš Edelsberger, Center Nr.: 42007	Krnov
Czechia	Jitka Hasalová, Center Nr.: 42010	Kromiz
Czechia	árka Drinková, Center Nr.: 42038	Lede Nad Sázavou
Czechia	Martina Košková, Center Nr.: 42047	Mladá Boleslav
Czechia	Dobromila Vykoupilová, Center Nr.: 42033	Nmice Nad Hanou
Czechia	Karel Churavý, Center Nr.: 42005	Nový Jiín
Czechia	árka Kubánková, Center Nr.: 42048	Nymburk
Czechia	Agentura Science Pro spol. s.r.o., Center Nr.: 42002	Olomouc
Czechia	Anna Rancová, Center Nr.: 42025	Olomouc
Czechia	Josef íný, Center Nr.: 42026	Opava
Czechia	MUDr.Tomáš Hrdina, Center Nr.: 42015	Opono
Czechia	Dr. Šeptáková, Center Nr.: 42074	Ostrava
Czechia	Jitka Homolová, Center Nr.: 42012	Ostrava
Czechia	MUDr. Eva Raická, Center Nr.: 42024	Ostrava
Czechia	Practice Dr. René Turínek, Center Nr.: 42034	Ostrava
Czechia	Radka Nágelová, Center Nr.: 42020	Ostrava Poruba
Czechia	AIDIN VK s.r.o., Center Nr.: 42017	Perov
Czechia	MUDr. Vra Prýmková, Center Nr.: 42070	Píbram
Czechia	Zdenk Jankovec, Center Nr.: 42044	Plze
Czechia	Diabetologická a interní ambulance, Center Nr.: 42064	Podbrady
Czechia	MUDr. Jana Houdová, Center Nr.: 42068	Praha
Czechia	Practice Dr. Milena Peterková, Center Nr.: 42063	Praha 2
Czechia	Jakub Hron, Center Nr.: 42043	Praha 4
Czechia	Markéta Hovorková, Center Nr.: 42042	Praha 4
Czechia	MUDr.Michala Pelikánová s.r.o., Center Nr.: 42055	Praha 4
Czechia	Jií Jón, Center Nr.: 42045	Praha 5
Czechia	Milan Fleka, Center Nr.: 42041	Praha 5
Czechia	Practice Dr. Lucie Kufová, Center Nr.: 42062	Praha 5
Czechia	Practice Dr. Ida Reissová, Center Nr.: 42056	Praha 6
Czechia	Barbora Diepoltová, Center Nr.: 42037	Praha 9
Czechia	Practice Dr. Petronela Janeková, Center Nr.: 42065	Rumburk
Czechia	Practice Dr. Miroslav Lindovský, Center Nr.: 42051	Sokolov
Czechia	Dana Fialkoviová, Center Nr.: 42040	Strakonice
Czechia	Marek Frydrych, Center Nr.: 42008	Tebí
Czechia	Marek Frydrych, Center Nr.: 42077	Tebí
Czechia	Diabetologická ambulance s.r.o., Center Nr.: 42076	Uherské Hradišt
Czechia	Dr. Hrmová, Center Nr.: 42073	Vlašim
Czechia	Lubomír Kudlej, Center Nr.: 42050	Vrchlabí
Czechia	AdiaMed s.r.o., Center Nr.: 42009	Vsetín
Czechia	EUC Klinika Zlín a.s., Center Nr.: 42075	Zlín
Czechia	Robin Urbánek, Center Nr.: 42029	Zlín
Hungary	Bajcsy-Zsilinszky Kórház és Rendelintézet, Center Nr.: 36019	Budapest
Hungary	Jahn Ferenc Dél-pesti Kórház és Rendelintézet, Center Nr.: 36014	Budapest
Hungary	Debreceni Egyetem Klinikai Központ, Kardiológiai Klinika, Center Nr.: 36006	Debrecen
Hungary	Kátai Gábor Kórház, Diabetológia Szakrendelés, Center Nr.: 36007	Karcag
Hungary	Practice Dr. Lelkesi Anita, Center Nr.: 36013	Mátészalka
Hungary	Nagyatádi Kórház, Center Nr.: 36021	Nagyatád
Hungary	Nyírségi Diabetes Centrum, Center Nr.: 36024	Nyíregyháza
Hungary	Dr. Wagner Zoltán, Center Nr.: 36020	Pécs
Hungary	Siófoki Kórház Rendelintézet, Center Nr.: 36004	Siófok
Hungary	Soproni Gyógyközpont, Center Nr.: 36018	Sopron
Poland	Gabinet Diabetologiczno- Internistyczny Katarzyna Wasilewska, Center Nr.: 48011	Biaystok
Poland	NZOZ DIAMED Sp. z o.o., Center Nr.: 48061	Czechowice-Dziedzice
Poland	Prywatny Gabinet Lekarski dr n. med. Joanna Sawer-Szewczyk, Center Nr.: 48055	Czyca
Poland	Zespó Opieki Zdrowotnej w czycy, Center Nr.: 48054	Czyca
Poland	NZOZ Sal Med, Center Nr.: 48047	Dzieroniów
Poland	Poradnia Diabetologiczna, Center Nr.: 48028	Gorlice
Poland	Indywidualna Specjalistyczna Praktyka Lekarska Piotr Piskozub Specjalista Diabetolog, Center Nr.: 48042	Jelenia Góra
Poland	NZOZ Poradnia Diabetologiczna, Center Nr.: 48038	Konin
Poland	Zakad Opieki Medycznej Sanatio; Sp. Z. o.o., Center Nr.: 48030	Kraków
Poland	Prywatny Gabinet Lekarski Tomasz Wierzykowski, Center Nr.: 48053	Kutno
Poland	Indywidualna Specjalistyczna Praktyka Lekarska Magorzata Poskoska-Lemaska, Center Nr.: 48035	Kwidzyn
Poland	Indywidualna Specjalistyczna Praktyka Lekarska Barbara Soróbka, Center Nr.: 48001	Legnica
Poland	Poradnia Cukrzycowa SP ZOZ w Lesku, Center Nr.: 48024	Lesko
Poland	Lumed Sp. z o.o., Center Nr.: 48032	Lubaczów
Poland	DIABETA-CARE Sp.z o.o., Center Nr.: 48008	Lubin
Poland	Poradnia Diabetologiczna Dr. mudziska, Center Nr.: 48013	Nako Nad Noteci
Poland	Alfa Specjalistyczne Gabinety Lekarskie Ewa Moroz, Center Nr.: 48007	Nowy Scz
Poland	Poradnia Diabetologiczna Dr. Adamczyk-Gajda, Center Nr.: 48031	Olenica
Poland	MED-ART Sp. z o.o., Center Nr.: 48052	Orzesze
Poland	Indywidualna Specjalistyczna Praktyka Lekarska Wiesawa Fischer, Center Nr.: 48020	Ostrów Wielkopolski
Poland	Prywatny Gabinet Lekarski azuka, Center Nr.: 48026	Parczew
Poland	Powiatowy Szpital Specjalistyczny w Stalowej Woli, Center Nr.: 48056	Stalowa Wola
Poland	Prywatny Gabinet Lekarski dr n. med. Piotr Gryglas, Center Nr.: 48059	Warszawa
Poland	Poradnia Diabetologiczna Szpitala Powiatowego w Wicborku, Center Nr.: 48003	Wicbork
Poland	Orodek Praktyka Lekarska Konrad Strzelczyk, Center Nr.: 48012	Woomin
Poland	Poradnia Diabetologiczna SPZZOZ w Wyszkowie, Center Nr.: 48067	Wyszków
Poland	Wojewódzka Poradnia dla Chorych na Cukrzyc, Center Nr.: 48025	Zabrze
Poland	Cardiomed, Center Nr.: 48019	Zielona Góra
Russian Federation	Anturium, Center Nr.: 70036	Barnaul
Russian Federation	Central city hospital, Center Nr.: 70073	Batajsk
Russian Federation	Chelyabinsk regional clinical hospital, Center Nr.: 70069	Chelyabinsk
Russian Federation	Limited Liability Company "Uralsky Medical Center", Center Nr.: 70063	Ekaterinburg
Russian Federation	Scientific and Practical Center of Specialized Types of Medical Care "Uralskij Institute of Cardiology", Center Nr.: 70079	Ekaterinburg
Russian Federation	Russian Medical Academy of Continuing Professional Education, Center Nr.: 70058	Irkutsk
Russian Federation	The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic, Center Nr.: 70037	Izhevsk
Russian Federation	Central City Hospital No. 18, Center Nr.: 70051	Kazan
Russian Federation	Kemerovo regional clinical hospital named S.V. Belyaev, Center Nr.: 70008	Kemerovo
Russian Federation	City Polyclinic No. 16, Center Nr.: 70067	Khabarovsk
Russian Federation	Kirov Clinical Hospital No. 7 named after V.I. Yurlova, Center Nr.: 70089	Kirov
Russian Federation	Krai clinical hospital Nr. 1 named after prof. S.V. Ochapovskogo, Center Nr.: 70049	Krasnodar
Russian Federation	Lipetsk Regional Hospital, Center Nr.: 70046	Lipetsk
Russian Federation	City Polyclinic No 107 of the Moscow City Healthcare Department, Center Nr.: 70082	Moscow
Russian Federation	City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70043	Moscow
Russian Federation	City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70045	Moscow
Russian Federation	Clinical Hospital No. 85 of trhe Federal Biomedical Agency, Center Nr.: 70042	Moscow
Russian Federation	SBIH Center for Speech Pathology and Neurorehabilitation MDH, Center Nr.: 70080	Moscow
Russian Federation	City Clinical Hospital named after V.V. Veresaeva of the Moscow Department of Health, Center Nr.: 70003	Moskau
Russian Federation	Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70032	Moskau
Russian Federation	Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70041	Moskau
Russian Federation	Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70081	Moskau
Russian Federation	Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70084	Moskau
Russian Federation	National Medical Research Center for Endocrinology, Center Nr.: 70025	Moskau
Russian Federation	Vessel Clinic, Center Nr.: 70011	Moskau
Russian Federation	City Polyclinic No. 1, Center Nr.: 70074	Nalchik
Russian Federation	City clinical hospital #12 of Sormovskiy district of Nizhniy Novgorod, Center Nr.: 70018	Nizhniy Novgorod
Russian Federation	Privolzhsky Research Medical University, Center Nr.: 70085	Nizhny Novgorod
Russian Federation	Novokuznetsk City Clinical Hospital No. 1, Center Nr.: 70050	Novokuznetsk
Russian Federation	AVICENNA, Center Nr.: 70064	Novosibirsk
Russian Federation	AVICENNA, Center Nr.: 70065	Novosibirsk
Russian Federation	City Clinical Polyclinic #16, Center Nr.: 70056	Novosibirsk
Russian Federation	Novosibirsk State Medical University, Center Nr.: 70059	Novosibirsk
Russian Federation	Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095	Penza
Russian Federation	City clinical hospital 5, Center Nr.: 70057	Perm
Russian Federation	City clinical hospital 5, Center Nr.: 70070	Perm
Russian Federation	Private Clinic Salon Roden, Center Nr.: 70086	Perm
Russian Federation	City polyclinic #16 of the City Rostov-on-Don, Center Nr.: 70027	Rostov-on-Don
Russian Federation	North-West State Medical University named after II. Mechnikov, Center Nr.: 70053	Saint Petersbug
Russian Federation	North-West State Medical University named after II. Mechnikov, Center Nr.: 70077	Saint Petersbug
Russian Federation	City Pokrovskaya Hospital, Center Nr.: 70022	Saint Petersburg
Russian Federation	Medilux-TM, Center Nr.: 70005	Saint Petersburg
Russian Federation	First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70024	Saint-Petersburg
Russian Federation	First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70087	Saint-Petersburg
Russian Federation	Samara city consulting and diagnostic polyclinic nr. 14, Center Nr.: 70029	Samara
Russian Federation	Samara city polyclinic Nr. 9 of Oktyabrskiy district, Center Nr.: 70028	Samara
Russian Federation	Clinical Hospital of the Saratov city, Center Nr.: 70090	Saratov
Russian Federation	LLC clinic "Family Doctor", Center Nr.: 70093	Saratov
Russian Federation	Multifunctional Medical Clinic "Sova", Center Nr.: 70030	Saratov
Russian Federation	AntMed, Center Nr.: 70034	St. Petersburg
Russian Federation	Dr. Tsiberkin, Center Nr.: 70048	St. Petersburg
Russian Federation	V.A. Almazov National Medical Research Center, Center Nr.: 70071	St. Petersburg
Russian Federation	Zabotlivyi Doktor, Center Nr.: 70016	St. Petersburg
Russian Federation	Regional Endocrinological Dispensary, Center Nr.: 70078	Stavropol
Russian Federation	Tyumen State Medical University, Center Nr.: 70066	Tyumen
Russian Federation	City clinical hospital, Center Nr.: 70019	Ufa
Russian Federation	City Polyclinic No.2, Center Nr.: 70062	Ulan-Ude
Russian Federation	Limited Liability Company "CENTER", Center Nr.: 70060	Vladivostok
Russian Federation	Regional Clinical Hospital No. 2, Center Nr.: 70068	Vladivostok
Russian Federation	Regional Clinical Hospital No. 2, Center Nr.: 70092	Vladivostok
Russian Federation	Clinical Polyclinic No.28, Center Nr.: 70040	Volgograd
Russian Federation	Volgograd Regional Clinical Hospital No. 3, Center Nr.: 70076	Volgograd
Russian Federation	State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70017	Voronezh
Russian Federation	State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70033	Voronezh
Russian Federation	State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70055	Voronezh
Russian Federation	Voronezh City Clinical Hospital #11, Center Nr.: 70035	Voronezh

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Bulgaria,  Czechia,  Hungary,  Poland,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist	Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist	Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported.; The concomitant T2D medications reported are: Metformin; Sulfonylurea; Acarbose; Pioglitazone; Insulin; Others	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist	Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported.; The reported concomitant CVD and/or chronic CKD medications are: Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs); Statins; Low dose aspirin; Beta blockers; Diuretics; Others	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The reported categories of gender are: Female; Male	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The reported categories of race are: Black; Non-black	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; The reported categories of gender are: Female; Male	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; The reported categories of race are: Black; Non-black	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; The reported categories of gender are: Female; Male	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; The reported categories of race are: Black; Non-black	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.; Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.; Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.; Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The reported categories of percentage (%) of glycosylated hemoglobin are: <8.5%; =8.5%; Missing	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.; The reported categories of percentage of glycosylated hemoglobin are: <8.5%; =8.5%; Missing	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.; The reported categories of percentage of glycosylated hemoglobin are: <8.5%; =8.5%; Missing	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Primary	Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Any Type of Cardiovascular Disease (CVD)	Number of patients with cardiovascular disease (CVD) is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment	Number of patients with chronic kidney disease (CKD) by physician's assessment (patients for whom CKD was reported as a comorbidity) is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status	Number of patients with documentation of estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) status is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status	Number of patients with Chronic Kidney Disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of the Different Types of Cardiovascular Disease	Number of patients in each category of the different types of cardiovascular disease is reported.; The following types of cardiovascular diseases are reported: Myocardial infarction; Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)); Ischemic heart disease; Congestive heart failure; Stroke; Peripheral arterial disease; The categories reported for each type of cardiovascular disease are: Yes; No; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography	Number of patients in each category of the different types of congestive heart failure (CHF) which was confirmed by echocardiography is reported.; The reported categories of congestive heart failure confirmed by echocardiography are: Yes; No; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist	Number of patients with any type of cardiovascular disease (CVD) or without CVD according to prescribing specialist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist	Number of patients with chronic kidney (CKD) and without CKD by physician's assessment according to prescribing specialist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist	Number of patients with chronic kidney disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status - according to prescribing specialist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.; Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients in each category of different types of cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.; The following types of cardiovascular diseases are reported: Myocardial infarction; Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)); Ischemic heart disease; Congestive heart failure; Stroke; Peripheral arterial disease; The categories reported for each type of cardiovascular disease are: Yes; No; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients in each category of congestive heart failure (CHF) confirmed by echocardiography according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) or without CKD by physician's assessment according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) and without CKD by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.; The categories of employment status are: Employed; Not employed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients in each category of family status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.; The categories of family status are: Single; Married; Divorced; Widowed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.; The categories of insurance status are: Not insured; Statutory insured; Privately insured; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The categories of employment status are: Employed; Not employed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The categories of family status are: Single; Married; Divorced; Widowed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The categories of insurance status are: Not insured; Statutory insured; Privately insured; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; The categories of employment status are: Employed; Not employed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; The categories of family status are: Single; Married; Divorced; Widowed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.; The categories of insurance status are: Not insured; Statutory insured; Privately insured; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; The categories of employment status are: Employed; Not employed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; The categories of family status are: Single; Married; Divorced; Widowed; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.; The categories of insurance status are: Not insured; Statutory insured; Privately insured; Unknown	At study index date 1 (i.e. between September 2018 and December 2018).
Secondary	Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.; The categories of status of T2D medication are: Discontinued; Continued	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The categories of status of T2D medication are: Discontinued; Continued	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.; The categories of status of T2D medication are: Discontinued; Continued	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.; The categories of status of T2D medication are: Discontinued; Continued	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication by country is reported.; The categories of reason for discontinuation of T2D medication are: Lack of efficacy; Medication administration; Financial burden regarding co-payment; Lost to follow-up; Adverse event; Other	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.; The categories of reason for discontinuation of T2D medication are: Lack of efficacy; Medication administration; Financial burden regarding co-payment; Lost to follow-up; Adverse event; Other	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.; The categories of reason for discontinuation of T2D medication are: Lack of efficacy; Medication administration; Financial burden regarding co-payment; Lost to follow-up; Adverse event; Other	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.; The categories of reason for discontinuation of T2D medication are: Lack of efficacy; Medication administration; Financial burden regarding co-payment; Lost to follow-up; Adverse event; Other	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.; The categories of reason for discontinuation of T2D medication are: Lack of efficacy; Medication administration; Financial burden regarding co-payment; Lost to follow-up; Adverse event; Other	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist	Number of patients for each type of physician specialties involved in decision for T2D therapy discontinuation according to prescribing specialist is reported.	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Secondary	Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication	Time to discontinuation of type 2 diabetes (T2D) treatment according to study medication is reported.; Time to discontinuation of T2D medication was estimated by Kaplan-Meier analysis. Patients who did not discontinue study medication at study index date 2 were censored.	From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..

External Links

•   Related Info